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Locked Nucleic Acid (LNA) is a unique nucleic-acid modification possessing very high binding
affinity and excellent specificity toward complementary RNA or DNA oligonucleotides. The remarkable
properties exhibited by LNA oligonucleotides have been employed in different nucleic acid-based
therapeutic strategies both in vitro and in vivo. Herein, we highlight the applications of LNA nucleotides
for controlling gene expression.
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1. Introduction. – In recent years, nucleic acids-based therapy has attracted
significant interest for the treatment of many diseases. It comprises several approaches
based on nucleic acid as the active component, which include antisense [1] [2],
ribozymes [2], short interfering RNA (siRNA) [2–4], microRNA (miRNA) [5] [6],
and aptamers [7–11]. Nucleic acids composed of naturally occurring DNA or RNA
nucleotides pose some limitations which directly affect the versatility because of their
poor binding affinity and low degree of nuclease resistance. To overcome these
limitations, chemically modified nucleic acids are introduced. A number of nucleic acid
analogues have been reported in recent years, among which locked nucleic acid (LNA)
modification has proved to be unique and has been used extensively for various
applications in chemical biology [12–19].
2. LNAChemistry and Key Features. – LNA is generally considered to be an RNA
mimic in which the ribose sugar moiety is locked by an oxymethylene bridge connecting
the C(2’)- and C(4’)-atoms which conformationally restricts LNA monomers (Fig. 1)
into an N-type sugar puckering [12] [15] [20]. Structural studies by NMR spectroscopy
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have shown LNA-containing oligonucleotides to fit into an A-type duplex geometry
[21] [22].
Several unique properties make LNA a very promising analogue in the field of
nucleic acids research. First and most importantly, LNA oligonucleotides possess
extremely high binding affinity to complementary DNA and RNA oligonucleotides, as
evidenced by thermal denaturation studies, i.e., an increase in melting temperature
(Tm) of þ2 to þ88 per LNAmonomer compared to the unmodified duplexes [12–16].
In addition, LNAs, as the sequence length can be reduced, also display an improved
mismatch discrimination (or improvedWatson–Crick base-pairing selectivity) relative
to unmodified nucleic acids. Furthermore, LNA-modified oligonucleotides show high
stability in biological systems (i.e., resistance to enzymatic degradation) [18] [19].
3. LNA in Therapeutics and Biotechnology. – Oligonucleotides can modulate gene
expression through binding of an antisense oligonucleotide (AON) to a specific
messenger RNA (mRNA; Fig. 2), pre-mRNA, or non-mRNA by Watson–Crick base
pairing. Various techniques include classical antisense approach, siRNA, microRNA
targeting, DNAzymes etc. For effective modulation of gene expression, the usefulness
of LNA-modified oligonucleotides has been the concept for many scientific inves-
tigations, and successful studies on LNA oligonucleotides for gene-silencing technol-
ogies have already been the topic of detailed reviews [23–25].
3.1.LNAAntisense. Majority of the antisense experiments conducted with LNA has
been focused on mRNA inhibition by RNase H recruitment, although non-RNase H
mechanisms have also been reported.Wahlestedt et al. first reported the effect of LNA
as an antisense molecule by demonstrating the feasibility of LNA to act as potent and
nontoxic nucleic acid modification in vivo [26]. The experiments involved two different
LNA sequences, an LNA/DNA mixmer and a LNA/DNA/LNA gapmer targeting the
delta opioid receptor (DOR) mRNA in the central nervous system of rats. An efficient
knockdown of DOR was induced in both the cases upon direct injection of the
oligomers into the rat brain. Thereafter, a number of reports highlighted a broad
potential of LNA-modified oligonucleotides in antisense-mediated gene-silencing
applications in vitro and in vivo (for reviews, see [23–25]). A recent report of Jacobsen
et al., for example, showed that LNA AONs are effective inhibitors of HIV-1
expression [27].
3.2. LNA-Modified DNAzyme (LNAzymes) for RNA Targeting. DNAzymes are
catalytically active DNA molecules that can function as a specific RNA endonuclease
upon binding to a specific RNA sequence [28] [29]. In this direction, Vester et al.
investigated the effect of LNA by incorporating two LNA nucleotides in each of the
Fig. 1. Structural representation of LNA monomers
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binding arms of the DNAzyme yielding an LNAzyme with a highly enhanced efficiency
of RNA cleavage [30]. The experiment demonstrated that the cleavage of highly
structured targets (a 58n-long RNAwith known secondary structure and a 2904n-long
23S ribosomal RNA) was significantly improved using LNAzymes compared to the
corresponding unmodified DNAzymes. A similar approach was employed by Schubert
et al. who incorporated 3–4 LNA monomers at the ends of the binding arms and
observed a highly enhanced efficiency of RNA cleavage [31]. In addition, they later
demonstrated that LNAzymes containing 3–4 LNA monomers at the ends of the
binding arms can cleave viral RNA structures that are resistant to hydrolysis by the
corresponding unmodified DNAzymes [32]. More recently, Jacobsen et al. reported an
efficient inhibition of HIV-1 expression by targeting LNAzymes to functionally
selected binding sites [27], whereas targeting of miRNAs by using LNAzymes has
recently been reported by Maiti and co-workers [33].
3.3. LNA-Modified siRNA (siLNA). Small interfering RNAs (siRNAs) have
emerged as powerful candidates for an efficient knockdown of gene expression in
mammalian cells by the RNA-interference (RNAi) pathway [34]. In this approach,
siRNA can target complementary mRNA and induce its degradation upon incorpo-
ration into the RNA-induced silencing complex (RISC). siRNA themselves are
candidates for incorporation of modified nucleotides for improved biostability, and/or
effective and selective RNA targeting. In this approach, the application of LNA-
modified siRNA, termed siLNA, has been investigated. Braasch et al. first conducted a
study in mammalian cells using LNA-modified siRNA and observed that the
introduction of LNA nucleotides substantially increased the thermal stability of the
modified RNA duplex without compromising the efficiency of RNAi [35]. Another
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Fig. 2. Schematic illustration of various nucleic acid-based therapeutic technologies
study by Elme´n et al. showed that systematically modified siRNA duplexes with LNA
monomers have remarkably enhanced serum half-life compared to the corresponding
unmodified siRNAs [36]. This report also highlighted an improved efficacy of siLNAs
on certain RNA motifs relevant for targeting the SARS-CoV virus in addition to
provide an evidence that the use of siLNAs reduces sequence related off-target effects.
Recently,Mook et al. evaluated the effect of LNA-modified siRNA both in vitro and in
vivo [37]. They showed that minimal LNA modifications at the 3’-end of siRNA are
effective to stabilize siRNA, and that multiple LNA modifications may lead to
decreased efficacy in vitro and in vivo. The study further revealed a reduced off-target
gene regulation when using LNA-modified siRNA compared to the unmodified
siRNA. Very recently, Bramsen et al. introduced a three-stranded siRNA construct
termed small internally segmented interfering RNA (sisiRNA) in which the antisense
strand is complexed with two short sense strands each of ca. 10–12 nt in length [38]. In
the sisiRNA approach, only the antisense strand is functional, as the nick completely
eliminates unintended mRNA targeting by the sense strand. LNA Nucleotides were
incorporated to stabilize the sisiRNA constructs, which proved efficient for gene
silencing upon transfection into a H1299 lung carcinoma cell line.
3.4. MicroRNA Targeting Using LNA Probes. MicroRNAs (miRNAs) constitute a
class of short regulatory RNAs (ca. 22 nt) that control gene expression post-
transcriptionally during development, differentiation, and metabolism [5] [6]. Similar
to classical AONs developed for the inhibition of coding RNAs, synthetic oligonucleo-
tides (antimiRs) are the only rational approach for specific inhibition of the individual
miRNAs and, therefore, have the potential to be developed as an important new class
of drugs. In this direction, the application of LNA modifications has been investigated
by Va´lo´czi et al. who described an efficient detection of miRNAs by northern blot
analysis using LNA-modified oligonucleotide probes and demonstrated their improved
sensitivity to detect different miRNAs in animals and plants [39]. Wienholds et al.
determined the temporal and spatial expression patterns of 115 conserved vertebrate
miRNAs in zebra fish embryos by in situ hybridizations using LNA-modified
oligonucleotide probes [40]. Another report highlighted a sensitive microarray
platform using LNA-modified capture probes for miRNA expression profiling [41].
More recently, Elme´n et al. described effective LNA antimiRs (LNA/DNA mixmer
oligonucleotides) with respect to miRNA silencing in non-human primates (target
liver-expressed miR-122) [42]. Their findings demonstrate the potential of these
compounds as new class of therapeutics for diseases associated with miRNAs.
4. LNA Aptamers. – Aptamers [7–11] are short DNA or RNA oligonucleotide
sequences that can bind to their targets with high affinity and specificity because of
their ability to adopt three-dimensional structures. Aptamers are generated by a
process referred to as SELEX (systematic evolution of ligands by exponential
enrichment) [43–46]. The remarkable properties and applications of LNAs highlighted
above, particularly their increased binding affinity and high degree of nuclease
resistance, substantiate the prospects of using aptamers composed of LNA-modified
nucleotides to rival aptamers composed of unmodified RNA or DNA. There are two
ways to introduce LNA modifications in aptamers. One is to evolve DNA/RNA
aptamers by conventional SELEX processes and then chemically modify the evolved
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aptamer sequences with LNA nucleotides (post-SELEX method). Another approach
is to use LNA-modified sequence libraries to generate LNA aptamers by a normal
SELEX-based strategy. So far, the use of LNA in aptamer technology has been limited
to the post-SELEX approach. In this direction, Darfeuille et al. introduced LNA
modifications to an existing RNA aptamer sequence targeting the trans-activation-
responsive (TAR) RNA element of HIV-1 [47] [48]. Surface plasmon resonance (SPR)
based experiments identified LNA/DNA mixmer oligonucleotides binding to TAR
RNAwith a dissociation constant in the low nanomolar range. Schmidt et al. described
the capability of LNA modifications to improve the in vivo stability of aptamers and
their targeting function [49]. Another work showed that an aptamer modified with
LNA nucleotides targeting the TAR RNA element of HIV-1 displayed good binding
properties and competed with the viral protein Tat for binding to TAR [50]. Further
studies from the same laboratory later led to an improved HIV-1 TAR element binding
by modifying a TAR RNA aptamer with LNA/2’-O-methyl RNA mixmers [51]. All of
these results show the potential of developing LNA aptamers and the need to evolve
LNA aptamers by conventional SELEX-based procedures. As a first step towards this
path, Veedu et al. has reported the synthesis and enzymatic incorporation of LNA
nucleotides into DNA and RNA oligonucleotides [52–55].
5. Conclusions and Future Prospects. – LNAOligonucleotides are versatile nucleic-
acid analogues with remarkable properties as improved hybridization properties for
applications in molecular biology research, biotechnology, and therapeutics. Based on
the results discussed above, LNA will likely be an important molecule for future
development of nucleic acid-based technologies. We envision that also LNA-based
aptamer technology will prove useful in developing nucleic-acid drugs against an array
of human diseases.
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